Clinical trialNCT02585713CompletedPhase 3Interventional

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

SponsorAcademic and Community Cancer Research UnitedEnrollment300Cerebral Vein ThrombosisDeep Vein ThrombosisGonadal ThrombosisHepatic ThrombosisMalignant NeoplasmMesenteric Thrombosis+6 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous thromboembolism. ADAM-VTE

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Robert McBane
Academic and Community Cancer Research United
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Northshore University Healthsystem-Evanston Hospital
Evanston, Illinois, United States
Illinois Cancercare-Peoria
Peoria, Illinois, United States
University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
Siouxland Regional Cancer Center
Sioux City, Iowa, United States
Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
Cancer Research Consortium of West Michigan Ncorp
Grand Rapids, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, United States
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
New Hampshire Oncology Hematology Pa-Hooksett
Hooksett, New Hampshire, United States
Firsthealth of the Carolinas-Moore Regional Hosiptal
Pinehurst, North Carolina, United States
Columbus Nci Community Oncology Research Program
Columbus, Ohio, United States
Toledo Clinic Cancer Centers-Toledo
Toledo, Ohio, United States
Guthrie Medical Group Pc-Robert Packer Hospital
Sayre, Pennsylvania, United States
Rapid City Regional Hospital
Rapid City, South Dakota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Apixaban →Dalteparin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Nov 2015
Primary completion: 2 Apr 2018
Completion: 24 Dec 2019
Last update posted: 4 Aug 2020
Registered enrollment: 300
Registry id: NCT02585713

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.